RxDoctor Payments Data

Joseph Dimeo, DO

Family Medicine · Yakima, WANPI 1205848942

Payments from drug & device makers

$8,777in general payments, 2019–2025

Across 460 payments — averaging $19.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • Pfizer$1K
  • AbbVie$757
  • GSK$696
  • Boehringer Ingelheim$660
  • Bayer$596
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$8,61298%
  • Education$1472%
  • Other$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,777 in reported general payments places this provider in the 95th percentile of 2,275 family medicine providers in Washington.

See all family medicine providers in Washington

Medicare billing

Part B allowed, 2024
$88,707
Medicare patients
166
Services billed
2,610

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide37$45,685
FarxigaDapagliflozin Propanediol31$28,302
MounjaroTirzepatide13$20,772
TrulicityDulaglutide16$19,962
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$14,673
MyrbetriqMirabegron18$12,995
LinzessLinaclotide19$12,708
Breo ElliptaFluticasone/Vilanterol11$7,833
EliquisApixaban11$6,303
InvokanaCanagliflozin12$5,604
JentaduetoLinagliptin/Metformin Hcl11$4,506
Ibandronate Sodium35$4,387
Levothyroxine Sodium228$2,181
Gabapentin126$2,012
Atorvastatin Calcium212$1,674

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$296$45,68537 claims
Lilly USA, LLCMounjaro, Trulicity$174$40,73429 claims
AstraZenecaFarxiga$2,088$28,30231 claims
GSKTrelegy Ellipta, Breo Ellipta$696$22,50628 claims
AbbVieLinzess, Synthroid$757$13,35437 claims
Astellas Pharma US IncMyrbetriq$153$12,99518 claims
PfizerEliquis$1,029$6,30311 claims
Johnson & JohnsonInvokana$325$5,60412 claims
Boehringer IngelheimJentadueto$660$4,50611 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,275 family medicine providers in Washington.

Other family medicine in Yakima

See the full list for Washington

Where these figures come from

Is this you, or does something look wrong? →